Literature DB >> 4010740

Heavy phenacetin use and bladder cancer in women aged 20 to 49 years.

J M Piper, J Tonascia, G M Matanoski.   

Abstract

We investigated the use of analgesics containing phenacetin or acetaminophen in 173 young women with urinary bladder cancer and 173 matched controls. The cases, who were 20 to 49 years old at the time of diagnosis of cancer, were 6.5 times more likely to report regular use of analgesics containing phenacetin at least one year before diagnosis than were their matched controls (odds ratio, 6.5; 95 per cent confidence interval, 1.5 to 59.2). Among the 15 women (13 cases and 2 controls) reporting regular use of phenacetin-containing drugs, 8 of the cases and 1 of the controls reported daily use for over one year (P = 0.04). Excessive use of analgesics containing acetaminophen was not reported. The increased risk of bladder cancer in young women who regularly used phenacetin-containing products remained present after adjustments for all other identified risk factors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4010740     DOI: 10.1056/NEJM198508013130504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  17 in total

1.  Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.

Authors:  Wassim Kassouf; Ashish M Kamat; Alexander Zlotta; Bernard H Bochner; Ronald Moore; Alan So; Jonathan Izawa; Ricardo A Rendon; Louis Lacombe; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

2.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

Review 3.  Aspirin and urologic cancer risk: an update.

Authors:  Cristina Bosetti; Valentina Rosato; Silvano Gallus; Carlo La Vecchia
Journal:  Nat Rev Urol       Date:  2012-01-24       Impact factor: 14.432

Review 4.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

5.  Morbidity of patients with analgesic-associated nephropathy on regular dialysis treatment and after renal transplantation.

Authors:  C Ballé; P Schollmeyer
Journal:  Klin Wochenschr       Date:  1990-01-04

6.  Comparison of the descriptive epidemiology of urinary tract cancers.

Authors:  S S Devesa; D T Silverman; J K McLaughlin; C C Brown; R R Connelly; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1990-09       Impact factor: 2.506

7.  Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study.

Authors:  Roland B Walter; Filippo Milano; Theodore M Brasky; Emily White
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

8.  Update on the management of non-muscle invasive bladder cancer.

Authors:  Saad Aldousari; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2010-02       Impact factor: 1.862

9.  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history.

Authors:  Erik Pasin; David Y Josephson; Anirban P Mitra; Richard J Cote; John P Stein
Journal:  Rev Urol       Date:  2008

10.  Analgesic-associated nephropathy.

Authors:  A Schwarz
Journal:  Klin Wochenschr       Date:  1987-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.